EGFR and non-small cell lung carcinoma: It is approved by the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) in China for the treatment of EGFR T790M mutation‐positive NSCLC, based on data from the AURA3 trial [5].